Is earlier better for melanoma checkpoint blockade?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30401867.
- Also identified by DOI 10.1038/s41591-018-0250-0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A neoadjuvant approach relying on the administration of combined anti-CTLA-4-anti-PD-1 treatment before lymph node surgery is evaluated in two phase 1 trials. Encouraging clinical, pathological and immunological responses to neoadjuvant therapy were observed, suggesting that this concept warrants further exploration; however, any future approach must address the unacceptably high toxicity of the regimens evaluated in these trials.
Medical subject headings
- CTLA-4 Antigen
- Immunotherapy
- Melanoma
- Programmed Cell Death 1 Receptor